pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-19a |
Genomic Coordinates | chr13: 91350891 - 91350972 |
Synonyms | MIRN19A, hsa-mir-19a, miR-19a, miRNA19A, MIR19A |
Description | Homo sapiens miR-19a stem-loop |
Comment | This sequence maps to chromosome 13 and is named miR-19a precursor-13 in reference . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-19a-5p | ||||||||||||||||||||||||||||||
Sequence | 14| AGUUUUGCAUAGUUGCACUACA |35 | ||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | MOB3B | ||||||||||||||||||||
Synonyms | C9orf35, MOB1D, MOBKL2B | ||||||||||||||||||||
Description | MOB kinase activator 3B | ||||||||||||||||||||
Transcript | NM_024761 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on MOB3B | |||||||||||||||||||||
3'UTR of MOB3B (miRNA target sites are highlighted) |
>MOB3B|NM_024761|3'UTR 1 TGCTCCACCTCACCCTTTGGAAGAAAGGAAAGCTGTTTCCTCCTGGTGCCCTGAGCGGGCAGGAGGTGGACCACCCTGGC 81 TGAAATGACACACCTACTCCCAGGAACAGCAGAGGTGGAGGCAAGCAGTGACTCCTGAGAGACATTCCCCACTCACTTTG 161 TGTGCTCTTAACCTTCTGAGTGCTGCTAGCCCAGACCTGTGGACGAGGCAGACCACAACGTGAAAGAAGGACCAGCCCCT 241 TGACCGTTCTGGCTGGGGAATTGTCCACGAGGAAGCCTCTGCACTTCCACACATGGCACAGTTCTGCCTGTGACCTGCCG 321 CCTAAGCTTTACTGGAATTCAGGTTTTGAGACTGAGATGCGTGTTCGTATTTTTCCACTTATCTGTCTTGTCAGCTGGCC 401 GACTTCTCTGTGATTGGTTTTTTAAGTGCCGGGTGAATTTTGGACCTCTGGATGTGCAGCAAGTTTTTATGCAATAAGCC 481 TTCCTTTCAGGTCTCTAAAAGCTCCTGCTCTGATCTGTGGTTTAACACTGTGCAGGGCTGTGGAGCTCTGAGACACCTGA 561 ACCCCTACCCATCCCCTGCACCTCCCTACTCTCCCTGCCGAGGCGTCCATAGCATTTCCCTAATAAATAGTTTTATCAGG 641 GACACTCCATGGGGTGGCTTGTCTCTGCCCCAAACAGGGTCTTCACGTTCTAACTGCAGGGAAGAGACTGGTTACTAGCG 721 TAAAGCTGACAAGTTACCAGTTCACCTGATCAGAATGTATTTTTTATAACCACCATCATTCCTTGTCTCTTCAGTGGAAG 801 ATATTCTTTCCTGTTTCCCAGAAGAGAGAAATAAAAGTCCTAAATAACTAAGAATGATCAGCGGGAGCGTTGGGCATGAT 881 TACTGCAGTGTTTGTTCTTTATTAAAGACAGGGAGTCGTGGCTGTCTCTACATAATACTAACATTTCAGTGAAAAAAGTA 961 CAATTGGTTATTTGGTACGTGTAGATTTAACACCCAGACGGCTGACTTGTAACCCTCCCCACTAGCCTTCTGAGCATTTA 1041 AACCCAGCCGTCATTCTCTCCCCACTCCACGCTCCCCACTCCTCTGCCACGTTATGTTACGGCACAAAATTAATTTCTGC 1121 CCCTGTGATTGGGCCACGGTTGCCAAGGTAACAGTGGAGCTGGAGCTAACTTCCTTCTTTCATCCTTTCCAATTTTTCTA 1201 TTCCAGAAGACAGTCAGAATAATGCATTCTGTACTACATCCTGCCTTTTGAAACCTAAATGAGTTTTCGTTGATGAAATG 1281 TTGCCTTCTCTGATTCATTCACAAAACTGTGGTGGTTCTGACCACCTGTGACGAGGGGGGTCATAATACTTCCAGTGATC 1361 CTTTTAATTTAGCAAAATATTTGTCGGTGGAGGGAAGTAGATAAGAATGTATTAGTGTATTTTAAAGTAATAATGATTAA 1441 AGAATAACTAAATGACTCTGATTTTGTTTTATCAATCATAATGTGTTAAAGCCCTCTGTGGCTGCCACAAAAGACTAGAA 1521 TCATGAAATCTTTGTCCAAGCTAAGAAAGGGCTGTCTCTGTGGGTACAGTGGCATTCTCTGTTGACCTAACCAAGCAGCC 1601 TGAACCTTGCTTTGTGTCTCGTAAAGGTCATCTCACGGAATCCAATTGCTGCTACCTCACCATGTTGCTGTGCCCTGGTC 1681 AACAATAAACATACTTTTGTCCCCCTTCCTAAGTAACTTTGAGAGGACAAGATAGGCAAAGTTTTTTCCCTACATCTCTT 1761 TTGGCCAAAAGAATATCTGACCATCACAGAGATCCAGAGAACAGAAACAAGAGCCCCTAAGTCCCAGCCTCTGCAATACA 1841 CAGTTACCAGATGGGAATGCAGCACAGTGGCACAGAGAGGTAACTACGGAGCCCATGCCCTGGAGGAACTCTGTAGCTGT 1921 GCATCATGGAACGCCACAGGATTTTTACATTAAAAAGTTGAATATGTTCCTGCATTTCAGCAGTGCATAATCGAGCAGGA 2001 GGCTGGAATCTGGAGACCTTTGTTATTCATTCTTTTTAAGGTTATTTTTTATTAACTGTGCATATGAAATTTCCACTCAA 2081 TTTAAAAATCCAAATCTTTTTAAGCTTCTTGGAAGAATTTCCTCCTGCTTATATTGTTAATTGCACTAATGAACTCTTCT 2161 AGGGTAAATTCTGGCAAACTACCCTTTTTTTTTTTTTAATCACAGAATATTCCTGTTCCCACAGAACTTTGGCACATTCT 2241 GAAGAAAATCTCTGCAGTCAATTTTTATCTCCTCTGCTTGACTGCATCTAACTGTTCATCTCTGTTATAAATGGAGCTTC 2321 AGCCCTCTGGGTCAGAGACTGACAACCCTCCTTCTTCTTCCTAACCTGTCCTACTCTCCTTCTTTTTCTGCTTTCATTTT 2401 AATTTTGGGAAATTTTAAAGTAAAAGTTTCAAAGTTGAAAGATTATAGTGAGTACCCTTATGTCCTTTAGTGCATCAGTT 2481 GTTAATGTTTTGCCTTGTTTTCTTTTCTTCCTTTTTTTTTTTTAAGAGAAGGGGTCTCTCCCTATTTTACCCAAGCTGGC 2561 CTTGAACCCCTTGCCTCAAGTGAGCTTCAACCTTAGCCTCCTGAGTAGCCAGGACTATGGCATGTACCACCGCACCTGCC 2641 TCACATTTTCTTTCTCACTGTAAATACACATTCTTATTCTTGAACCTTCTGAAAATAAGTTGCAGACATCATGAAAATGT 2721 AAAATACTTCATCATATTCTTTCTTTTAATAAGAGCATTGTCCTATAAATCTGCAATATTTTCACGCCCATGAAACTGAA 2801 CACTGATACTGCATAAATCTAATATATGATCCATATTCAAAATTCTCCAGTTGTCCCCAAAATATCCTTTATAGCTGTTT 2881 ATTTTTAAATCCAGGATCCAATCAAGAATTATACGTTATATGTAGTTGTCATTCTCTTTTGTTTCCTTTAATTGATTAGA 2961 GTTGCCCTTTTGTGTGTGTCTGAGTGGTGGGTGGTGGGGTGGTGTTTGTGTATGATGTGCAGTGTGTGTGTGTGTGGTGT 3041 GTCTTTCATGACACTGACATTATTAAAGAGTTCAGGCAAGTTTGTGGAATGTCCCACAATCTAGACTTTTTTACTGATTG 3121 TTTCCTCATTACGAGATACAGGTTACATTTTTTTTCCCAAGACTGCTACATGTGTGATGTTGTTTCCTTACTACTGCCTC 3201 ACCTCAGGAAGCACATAATGTCTACTTGTCTCTTTTCTGATATTAGGACTGATCAGGTGTTGTCTGCCTGATCCAATCAT 3281 TATCAAGTTCCATAATTCATTATTAAGCTCTGAAATTCAGGACACATACATTTATAGAGTGTGAGGCTGTGCATACGTAC 3361 ATTCATCCCTTAATGTTCTCAAGGAGGCCCAGGATCCCCAAAATATTATAAGCATTGCAGTCAGATGATATAGCACTAGC 3441 AAAGCATTCATCCCTTTCCATATAACAGGAGGGAGGGGAAGAAGGAAGTTTCCATGTGCAGGCAATACGTGAGAGCATGG 3521 GCAAGTGAGGATTTGTATGCTCCCTGTAGCCAGAGGTGAAATATTCAACGCTTTTATTTTTTCTCCCGTCTTCAATGACC 3601 TCCCATTTGGACCCATAGTTTATTTATAGAGAGCACACACTCCCTAATTGTCAGATGGTTTTTTTGGGAAAACTCTTAGA 3681 TAGTACAGTGAGTTGTGACCCTCCAAAGGATCACAAGTACATAAACAGATACAAAGTATTTATGTGGTATTAAAATTTCA 3761 TGGTGATGGTGCAAGGGAGAGATGATTAGGAAGAAAATGTCTTACACGGCTGTAATTGAGAAATACTGATCTAGAGTCAT 3841 TTCCTGCTTCTTAAATTGTTCGTTTTCTCTTCCCTGGGTATTTTCTCATTTCCAAAGACCCAGAGTCTCAGAGCCAGGTT 3921 AAGTGGAAGAAACTTTGAGAGGTTTCTTAATCAATTCCTTCTATCTCTCAAACCATGCCAGTAACTTCCTTGGTGAAAAA 4001 ATCTATACTCCTCTCACAGTTCTTCGGGCATGGAAATTCTATAGCATTCTTTGGTATAACCAACCCACTGAACCCTCCAC 4081 AACATCTTGAATTCCATTCAACTCGAGCTGAAGTATTCTTTTTGAGTTTCAGTATATCTTTTCTAGTGTCCCACTTTTAG 4161 AAAGGTCCAAAGATGATATATAATAAGTGAAAATACAATTAATCAGAGCTTTATTTGCATATCCATTAAATATCTGAAGG 4241 CTATTACCAGTTGTGCTTCAGCCTCCTTTCCCTTGCAATTCTCCCAGGGTGGCATCCTCTACGGAGTCTTGTTGCTCCAT 4321 TGTTGACCACTGATGTAACTCAACGTGAAACCTTCCCAAAGCTCTCCACATCACTCTCTGTTATGGCTGTGACCAGCAGT 4401 GAACATGAAAAGAACTTATTTCATGCCTTCTCCAAACTATATTGTTTCTTTGCTAAGTCCAGACCTGCTTTTTCTACATT 4481 TATAGGTTTTCTATTTTAATCGCCATGCAAAATTCTTTATCATACTCAATCATTTTGGTTTATCTTCCTGACTTCTTACC 4561 TTTAACATCCCTGTTAAAGATTACACTGTTGTTGTTTCAAAAAAAAAAAAAAAAAAACCTTAATTGGCAAAACATTAAGG 4641 GACTTGAATAGAATTACACTTATCTTTTTGTGCTGATTTATGTCAATCCATCATTCTGGTTATTGATGGAAGCAAATTGC 4721 TTCCTATGTTCTCTAAACCTTATGTCCCTTCCATACTCCATGAGTACCACACTGGGAGAAAACAAAAGCAAAAAGATTGT 4801 GGGAAAAGTATAGCCATTATCTTTGAGGAAATGTGTACCAAGGCACAATCATTAAAAGGAGTTGGAGGCATCATTTGGTT 4881 GACACTGTTGTCATTCTTGTTCTGATCATTTTGGACCTTGAAGAAATTGGTGATTCTCTCCTAGAATTAGACAAACAAAG 4961 TGTGTTTGGAAATAATGATTGTTTTCCTGCCTTAAAAAATATATTAACAGAAAGCTTTTATAACAGGCTGTTTCCCTCTG 5041 GACAGGTATTAATTCTGAGTAAGAATTTTCAGTGACTACATAAGGATTTGTGTAACTTATGAAGGAAGAGTCCATTTCTA 5121 ATCAAATAATTCGCCTGTTTTACTAGCTTATAGTGATCTGATTTCAGAATTTTCCTGTATCTTTTTTACATACATCAGAA 5201 AAAGAAATGTTTACTATATTTTTGGTTCCATTTATGATTGTATTAAGCATTTGACTATAAGGAAAACTAACAATTAAATC 5281 AATTAGAAAAGCAACATAAAATTAAATGATATTTAGGAAATCAGTTATATGTGAGCTTGGGTATTCAAATGTCACAAATA 5361 AAAAGCATATAACCATTAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | BC-3 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796039. RNA binding protein: AGO2. Condition:4-Thiouridine
PAR-CLIP data was present in GSM796040. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
CLIP-seq Support 1 for dataset GSM796039 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-3 / 4-Thiouridine |
Location of target site | ENST00000262244.5 | 3UTR | UUGGCAAAACAUUAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM796040 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-3 / 4-Thiouridine |
Location of target site | ENST00000262244.5 | 3UTR | UUGGCAAAACAUUAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
92 hsa-miR-19a-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT038980 | WDR96 | cilia and flagella associated protein 43 | 1 | 1 | ||||||||
MIRT063864 | RASSF8 | Ras association domain family member 8 | 2 | 6 | ||||||||
MIRT077656 | IGF2BP1 | insulin like growth factor 2 mRNA binding protein 1 | 2 | 2 | ||||||||
MIRT078461 | MAP3K3 | mitogen-activated protein kinase kinase kinase 3 | 2 | 2 | ||||||||
MIRT095248 | FAM13B | family with sequence similarity 13 member B | 2 | 2 | ||||||||
MIRT109490 | KLHL15 | kelch like family member 15 | 2 | 6 | ||||||||
MIRT155378 | CCNT2 | cyclin T2 | 2 | 2 | ||||||||
MIRT163208 | EDEM1 | ER degradation enhancing alpha-mannosidase like protein 1 | 2 | 2 | ||||||||
MIRT188326 | ARID1A | AT-rich interaction domain 1A | 2 | 2 | ||||||||
MIRT204723 | BZW1 | basic leucine zipper and W2 domains 1 | 2 | 4 | ||||||||
MIRT236399 | HMGXB4 | HMG-box containing 4 | 2 | 2 | ||||||||
MIRT237114 | P2RY1 | purinergic receptor P2Y1 | 2 | 5 | ||||||||
MIRT286942 | SOCS7 | suppressor of cytokine signaling 7 | 2 | 2 | ||||||||
MIRT442523 | MOB3B | MOB kinase activator 3B | 2 | 2 | ||||||||
MIRT473428 | MDM4 | MDM4, p53 regulator | 2 | 2 | ||||||||
MIRT476783 | FOS | Fos proto-oncogene, AP-1 transcription factor subunit | 2 | 2 | ||||||||
MIRT476942 | FAM83G | family with sequence similarity 83 member G | 2 | 2 | ||||||||
MIRT480184 | CALM2 | calmodulin 2 | 2 | 6 | ||||||||
MIRT489620 | ZNF384 | zinc finger protein 384 | 2 | 2 | ||||||||
MIRT492246 | SLC39A9 | solute carrier family 39 member 9 | 2 | 2 | ||||||||
MIRT492422 | RGL2 | ral guanine nucleotide dissociation stimulator like 2 | 2 | 2 | ||||||||
MIRT494860 | ZNF99 | zinc finger protein 99 | 2 | 2 | ||||||||
MIRT497001 | SNAP25 | synaptosome associated protein 25 | 2 | 2 | ||||||||
MIRT501973 | MAPK6 | mitogen-activated protein kinase 6 | 2 | 2 | ||||||||
MIRT504917 | CD38 | CD38 molecule | 2 | 4 | ||||||||
MIRT507019 | HMGA2 | high mobility group AT-hook 2 | 2 | 6 | ||||||||
MIRT510820 | SBNO1 | strawberry notch homolog 1 | 2 | 4 | ||||||||
MIRT514166 | PGPEP1 | pyroglutamyl-peptidase I | 2 | 2 | ||||||||
MIRT514328 | PSMG2 | proteasome assembly chaperone 2 | 2 | 4 | ||||||||
MIRT514429 | SLC38A7 | solute carrier family 38 member 7 | 2 | 2 | ||||||||
MIRT514537 | ESR2 | estrogen receptor 2 | 2 | 2 | ||||||||
MIRT516117 | SRPX2 | sushi repeat containing protein, X-linked 2 | 2 | 4 | ||||||||
MIRT517759 | ZNF366 | zinc finger protein 366 | 2 | 4 | ||||||||
MIRT518495 | FAM161B | family with sequence similarity 161 member B | 2 | 4 | ||||||||
MIRT518512 | CASP10 | caspase 10 | 2 | 2 | ||||||||
MIRT518561 | GDPD1 | glycerophosphodiester phosphodiesterase domain containing 1 | 2 | 2 | ||||||||
MIRT518641 | NOM1 | nucleolar protein with MIF4G domain 1 | 2 | 2 | ||||||||
MIRT518729 | ABCG8 | ATP binding cassette subfamily G member 8 | 2 | 2 | ||||||||
MIRT523565 | GGCX | gamma-glutamyl carboxylase | 2 | 4 | ||||||||
MIRT526523 | YIPF6 | Yip1 domain family member 6 | 2 | 2 | ||||||||
MIRT530254 | ZNF620 | zinc finger protein 620 | 2 | 2 | ||||||||
MIRT531658 | ZFP14 | ZFP14 zinc finger protein | 2 | 2 | ||||||||
MIRT532699 | TCN2 | transcobalamin 2 | 2 | 4 | ||||||||
MIRT534019 | STXBP4 | syntaxin binding protein 4 | 2 | 2 | ||||||||
MIRT535748 | MYO10 | myosin X | 2 | 4 | ||||||||
MIRT544509 | GTF2E2 | general transcription factor IIE subunit 2 | 2 | 2 | ||||||||
MIRT546758 | RLIM | ring finger protein, LIM domain interacting | 2 | 2 | ||||||||
MIRT547929 | HNRNPR | heterogeneous nuclear ribonucleoprotein R | 2 | 2 | ||||||||
MIRT550130 | ZNF138 | zinc finger protein 138 | 2 | 2 | ||||||||
MIRT551763 | MED21 | mediator complex subunit 21 | 2 | 2 | ||||||||
MIRT557727 | FYCO1 | FYVE and coiled-coil domain containing 1 | 2 | 2 | ||||||||
MIRT558924 | CBX1 | chromobox 1 | 2 | 2 | ||||||||
MIRT562466 | CORO1C | coronin 1C | 2 | 2 | ||||||||
MIRT562759 | ZNF846 | zinc finger protein 846 | 2 | 2 | ||||||||
MIRT563061 | ZNF28 | zinc finger protein 28 | 2 | 2 | ||||||||
MIRT563336 | RPLP0 | ribosomal protein lateral stalk subunit P0 | 2 | 2 | ||||||||
MIRT569170 | DMD | dystrophin | 2 | 2 | ||||||||
MIRT573256 | TNFAIP6 | TNF alpha induced protein 6 | 2 | 2 | ||||||||
MIRT575057 | P2ry1 | purinergic receptor P2Y, G-protein coupled 1 | 2 | 4 | ||||||||
MIRT575360 | Zxda | zinc finger, X-linked, duplicated A | 2 | 2 | ||||||||
MIRT613233 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT613347 | ADRBK2 | G protein-coupled receptor kinase 3 | 2 | 6 | ||||||||
MIRT613952 | TMEM59 | transmembrane protein 59 | 2 | 2 | ||||||||
MIRT615488 | EDN1 | endothelin 1 | 2 | 2 | ||||||||
MIRT618710 | ESD | esterase D | 2 | 2 | ||||||||
MIRT630609 | ARHGAP1 | Rho GTPase activating protein 1 | 2 | 2 | ||||||||
MIRT630619 | CXCR6 | C-X-C motif chemokine receptor 6 | 2 | 2 | ||||||||
MIRT630631 | IMPAD1 | inositol monophosphatase domain containing 1 | 2 | 2 | ||||||||
MIRT630674 | KLF7 | Kruppel like factor 7 | 2 | 2 | ||||||||
MIRT630746 | COG6 | component of oligomeric golgi complex 6 | 2 | 2 | ||||||||
MIRT636853 | ZSCAN2 | zinc finger and SCAN domain containing 2 | 2 | 2 | ||||||||
MIRT638642 | GPATCH8 | G-patch domain containing 8 | 2 | 2 | ||||||||
MIRT639106 | MMAB | methylmalonic aciduria (cobalamin deficiency) cblB type | 2 | 2 | ||||||||
MIRT639422 | PKP1 | plakophilin 1 | 2 | 2 | ||||||||
MIRT640187 | ABCC12 | ATP binding cassette subfamily C member 12 | 2 | 2 | ||||||||
MIRT641757 | SF3A1 | splicing factor 3a subunit 1 | 2 | 2 | ||||||||
MIRT666577 | RHOBTB3 | Rho related BTB domain containing 3 | 2 | 2 | ||||||||
MIRT672166 | FANCF | Fanconi anemia complementation group F | 2 | 2 | ||||||||
MIRT688345 | ETS1 | ETS proto-oncogene 1, transcription factor | 2 | 2 | ||||||||
MIRT690120 | ZFAND1 | zinc finger AN1-type containing 1 | 2 | 2 | ||||||||
MIRT696939 | CERK | ceramide kinase | 2 | 2 | ||||||||
MIRT701361 | NR4A3 | nuclear receptor subfamily 4 group A member 3 | 2 | 2 | ||||||||
MIRT703288 | GID4 | GID complex subunit 4 homolog | 2 | 2 | ||||||||
MIRT709146 | ZNF799 | zinc finger protein 799 | 2 | 2 | ||||||||
MIRT710848 | FAM210A | family with sequence similarity 210 member A | 2 | 2 | ||||||||
MIRT712621 | GTF2H5 | general transcription factor IIH subunit 5 | 2 | 2 | ||||||||
MIRT714591 | CMBL | carboxymethylenebutenolidase homolog | 2 | 2 | ||||||||
MIRT716909 | CACNB2 | calcium voltage-gated channel auxiliary subunit beta 2 | 2 | 2 | ||||||||
MIRT721165 | FAM200B | family with sequence similarity 200 member B | 2 | 2 | ||||||||
MIRT722404 | BCAS2 | BCAS2, pre-mRNA processing factor | 2 | 2 | ||||||||
MIRT722517 | DSTYK | dual serine/threonine and tyrosine protein kinase | 2 | 2 | ||||||||
MIRT724599 | AP3B1 | adaptor related protein complex 3 beta 1 subunit | 2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|